Paul S Haber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1876305/publications.pdf

Version: 2024-02-01

208 papers 6,917 citations

66343 42 h-index 76900 74 g-index

212 all docs 212 docs citations

times ranked

212

7910 citing authors

#	Article	IF	CITATIONS
1	Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet, The, 2007, 370, 1915-1922.	13.7	611
2	Activation of Pancreatic Stellate Cells in Human and Experimental Pancreatic Fibrosis. American Journal of Pathology, 1999, 155, 1087-1095.	3.8	382
3	Expression of the Gene for Multidrug-Resistance–Associated Protein and Outcome in Patients with Neuroblastoma. New England Journal of Medicine, 1996, 334, 231-238.	27.0	295
4	Alcohol use disorders. Lancet, The, 2016, 387, 988-998.	13.7	277
5	Prevalence and correlates of DSMâ€IV alcohol abuse and dependence in Australia: findings of the 2007 National Survey of Mental Health and Wellbeing. Addiction, 2010, 105, 2085-2094.	3.3	203
6	An overview of the patterns of prescription opioid use, costs and related harms in <scp>A</scp> ustralia. British Journal of Clinical Pharmacology, 2014, 78, 1159-1166.	2.4	172
7	Clearance of Hepatitis C Viremia Associated with Cellular Immunity in the Absence of Seroconversion in the Hepatitis C Incidence and Transmission in Prisons Study Cohort. Journal of Infectious Diseases, 2004, 189, 1846-1855.	4.0	147
8	Naltrexone versus acamprosate in the treatment of alcohol dependence: a multiâ€centre, randomized, doubleâ€blind, placeboâ€controlled trial. Addiction, 2006, 101, 1451-1462.	3.3	143
9	Pathogenesis of alcoholâ€induced liver disease: Classical concepts and recent advances. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1089-1105.	2.8	138
10	Alcoholic Liver Disease in Asia, Europe, and North America. Gastroenterology, 2016, 150, 1786-1797.	1.3	133
11	Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology, 2019, 236, 2713-2724.	3.1	130
12	PREDICTORS OF RELAPSE TO HARMFUL ALCOHOL AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Alcohol and Alcoholism, 2006, 41, 278-283.	1.6	113
13	Management of injecting drug users admitted to hospital. Lancet, The, 2009, 374, 1284-1293.	13.7	99
14	Pharmacotherapeutic agents in the treatment of methamphetamine dependence. Expert Opinion on Investigational Drugs, 2017, 26, 563-578.	4.1	97
15	Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry,the, 2018, 5, 957-960.	7.4	94
16	Quantitation of fibroblast activation protein (FAP)â€specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio, 2014, 4, 43-54.	2.3	89
17	Metabolism of ethanol by rat pancreatic acinar cells. Translational Research, 1998, 132, 294-302.	2.3	87
18	Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. British Journal of Psychiatry, 2018, 212, 362-369.	2.8	87

#	Article	IF	Citations
19	Unplanned pregnancy and contraceptive use in women attending drug treatment services. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2012, 52, 146-150.	1.0	85
20	Gene Expression Profiling of Alcoholic Liver Disease in the Baboon (Papio hamadryas) and Human Liver. American Journal of Pathology, 2003, 163, 2303-2317.	3.8	78
21	Longâ€term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outâ€patients with opioid use disorder. Addiction, 2019, 114, 1416-1426.	3.3	75
22	Incidence and risk for acute hepatitis C infection during imprisonment in Australia. European Journal of Epidemiology, 2010, 25, 143-148.	5.7	74
23	Intrahepatic gene expression in human alcoholic hepatitis. Journal of Hepatology, 2006, 45, 306-320.	3.7	65
24	Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction, 2016, 111, 311-319.	3.3	63
25	Pathogenesis and management of alcoholic hepatitis. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 1332-1344.	2.8	61
26	SMART amplification maintains representation of relative gene expression: quantitative validation by real time PCR and application to studies of alcoholic liver disease in primates. Journal of Proteomics, 2003, 55, 53-66.	2.4	61
27	Cystic fibrosis genotypes and alcoholic pancreatitis. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 496-499.	2.8	57
28	Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. Medical Journal of Australia, 2001, 174, 183-184.	1.7	57
29	Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?. Addiction, 2008, 103, 953-959.	3.3	57
30	Examining Perceived Stress, Childhood Trauma and Interpersonal Trauma in Individuals With Drug Addiction. Psychological Reports, 2019, 122, 433-450.	1.7	55
31	Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine. JAMA Network Open, 2021, 4, e219041.	5.9	55
32	A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Preventive Medicine, 2013, 57, 297-303.	3.4	54
33	Genomeâ€wide Association Study and Metaâ€analysis on Alcoholâ€Associated Liver Cirrhosis Identifies Genetic Risk Factors. Hepatology, 2021, 73, 1920-1931.	7.3	54
34	Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. Journal of Hepatology, 2011, 55, 76-85.	3.7	53
35	Transmission of hepatitis C within Australian prisons. Medical Journal of Australia, 1999, 171, 31-33.	1.7	51
36	Probabilistic reward- and punishment-based learning in opioid addiction: Experimental and computational data. Behavioural Brain Research, 2016, 296, 240-248.	2.2	51

#	Article	IF	Citations
37	Direct effects of alcohol on hepatic fibrinolytic balance: Implications for alcoholic liver disease. Journal of Hepatology, 2008, 48, 614-627.	3.7	48
38	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. Frontiers in Psychiatry, 2018, 9, 708.	2.6	47
39	Non-Oxidative Metabolism of Ethanol by Rat Pancreatic Acini. Pancreatology, 2004, 4, 82-89.	1.1	45
40	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. International Journal of Drug Policy, 2015, 26, 976-983.	3.3	44
41	Systematic Reviews of Mindfulness and Acceptance and Commitment Therapy for Alcohol Use Disorder: Should we be using Third Wave Therapies?. Alcohol and Alcoholism, 2019, 54, 159-166.	1.6	44
42	Alcohol use disorder and circulating cytokines: A systematic review and meta-analysis. Brain, Behavior, and Immunity, 2020, 89, 501-512.	4.1	44
43	Osteopontin is an important mediator of alcoholic liver disease <i>via</i> hepatic stellate cell activation. World Journal of Gastroenterology, 2014, 20, 13088.	3.3	44
44	Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Medical Journal of Australia, 2010, 192, 496-500.	1.7	43
45	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre―and postâ€universal access to directâ€acting antiviral treatment in Australia: The LiveRLife study. Journal of Viral Hepatitis, 2020, 27, 281-293.	2.0	39
46	Effect of pegylated interferonâ€Î±â€2a treatment on mental health during recent hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 957-965.	2.8	38
47	A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian Prisoners. PLoS ONE, 2014, 9, e87564.	2.5	38
48	THE EFFECTIVENESS OF A TAILORED INTERVENTION FOR EXCESSIVE ALCOHOL CONSUMPTION PRIOR TO ELECTIVE SURGERY. Alcohol and Alcoholism, 2006, 41, 643-649.	1.6	37
49	Alcopops, taxation and harm: a segmented time series analysis of emergency department presentations. BMC Public Health, 2015, 15, 468.	2.9	35
50	General practitioners' diagnostic skills and referral practices in managing patients with drug and alcohol-related health problems: implications for medical training and education programmes. Drug and Alcohol Review, 2003, 22, 417-424.	2.1	34
51	National trends in alcohol pharmacotherapy: Findings from an Australian claims database. Drug and Alcohol Dependence, 2016, 166, 254-257.	3.2	34
52	Issues with recruitment to randomised controlled trials in the drug and alcohol field: a literature review and Australian case study. Drug and Alcohol Review, 2008, 27, 115-122.	2.1	33
53	Alcohol, Signaling, and ECM Turnover. Alcoholism: Clinical and Experimental Research, 2010, 34, 4-18.	2.4	33
54	Circulating Lipids Are Associated with Alcoholic Liver Cirrhosis and Represent Potential Biomarkers for Risk Assessment. PLoS ONE, 2015, 10, e0130346.	2.5	33

#	Article	IF	Citations
55	Evaluation of a novel method for the analysis of alcohol biomarkers: Ethyl glucuronide, ethyl sulfate and phosphatidylethanol. Alcohol, 2018, 67, 7-13.	1.7	33
56	Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients $\hat{a} \in \mathbb{M}$ experiences in Australia. Drug and Alcohol Dependence, 2021, 227, 108959.	3.2	33
57	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. Journal of Hepatology, 2022, 76, 275-282.	3.7	33
58	Detection of Δ ⁹ THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two pointâ€ofâ€collection testing devices. Drug Testing and Analysis, 2019, 11, 1486-1497.	2.6	32
59	The efficacy of compliance therapy in pharmacotherapy for alcohol dependence: a randomized controlled trial Journal of Studies on Alcohol and Drugs, 2005, 66, 833-841.	2.3	31
60	Inflammation and Repair in Viral Hepatitis C. Digestive Diseases and Sciences, 2008, 53, 1468-1487.	2.3	31
61	Some new directions for research on psychological interventions for comorbid anxiety and substance use disorders. Drug and Alcohol Review, 2010, 29, 518-524.	2.1	31
62	Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment. Drug and Alcohol Review, 2007, 26, 231-239.	2.1	30
63	Expectancy in Double-Blind Placebo-Controlled Trials: An Example from Alcohol Dependence. Psychotherapy and Psychosomatics, 2009, 78, 167-171.	8.8	29
64	Brief Report: Genetics of Alcoholic Cirrhosisâ€" <scp>G</scp> enom <scp>ALC</scp> Multinational Study. Alcoholism: Clinical and Experimental Research, 2015, 39, 836-842.	2.4	29
65	Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. Journal of Substance Abuse Treatment, 2012, 43, 440-445.	2.8	28
66	Intolerance of uncertainty in opioid dependency – Relationship with trait anxiety and impulsivity. PLoS ONE, 2017, 12, e0181955.	2.5	28
67	Impact of acutely behavioural disturbed patients in the emergency department: A prospective observational study. EMA - Emergency Medicine Australasia, 2019, 31, 387-392.	1.1	28
68	The efficacy of an opportunistic cognitive behavioral intervention package (OCB) on substance use and comorbid suicide risk: A multisite randomized controlled trial Journal of Consulting and Clinical Psychology, 2014, 82, 130-140.	2.0	27
69	Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. Drug and Alcohol Dependence, 2017, 181, 132-139.	3.2	27
70	Learning and generalization from reward and punishment in opioid addiction. Behavioural Brain Research, 2017, 317, 122-131.	2.2	27
71	Biased and less sensitive: A gamified approach to delay discounting in heroin addiction. Journal of Clinical and Experimental Neuropsychology, 2018, 40, 139-150.	1.3	27
72	A Mobile Text Message Intervention to Reduce Repeat Suicidal Episodes: Design and Development of Reconnecting After a Suicide Attempt (RAFT). JMIR Mental Health, 2017, 4, e56.	3.3	27

#	Article	IF	Citations
73	The influence of alcohol and tobacco use in orthopaedic inpatients on complications of surgery. Drug and Alcohol Review, 2008, 27, 55-64.	2.1	26
74	Patatin-like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. Hepatology, 2010, 51, 1463-1465.	7.3	26
75	Understanding and Treating Patients With Alcoholic Cirrhosis: An Update. Alcoholism: Clinical and Experimental Research, 2009, 33, 1136-1144.	2.4	25
76	Hippocampal glutamate is increased and associated with risky drinking in young adults with major depression. Journal of Affective Disorders, 2015, 186, 95-98.	4.1	25
77	Cue Exposure Therapy for Alcohol Use Disorders: What Can Be Learned from Exposure Therapy for Anxiety Disorders?. Substance Use and Misuse, 2019, 54, 2053-2063.	1.4	25
78	Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. American Journal of Gastroenterology, 2021, 116, 106-115.	0.4	25
79	Detection of and intervention for excessive alcohol and tobacco use among adult hospital in-patients. Drug and Alcohol Review, 2007, 26, 127-133.	2.1	24
80	Alcohol and the pancreas. Addiction Biology, 1998, 3, 137-150.	2.6	23
81	Unplanned admissions to two Sydney public hospitals after naltrexone implants. Medical Journal of Australia, 2008, 188, 441-444.	1.7	23
82	Pre-operative screening for excessive alcohol consumption among patients scheduled for elective surgery. Drug and Alcohol Review, 2007, 26, 119-125.	2.1	22
83	Down-regulation of liver $Gall^21$, $4GlcNAcled{1}$ 1 , 4 -sialyltransferase gene by ethanol significantly correlates with alcoholic steatosis in humans. Metabolism: Clinical and Experimental, 2008, 57, 1663-1668.	3.4	22
84	The Clinical and Theoretical Basis for Integrated Cognitive Behavioral Treatment of Comorbid Social Anxiety and Alcohol Use Disorders. Cognitive and Behavioral Practice, 2015, 22, 504-521.	1.5	22
85	Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings. Addiction, 2022, 117, 382-391.	3.3	22
86	Risk Factors for Hepatitis C Infection and Perception of Antibody Status among Male Prison Inmates in the Hepatitis C Incidence and Transmission in Prisons Study Cohort, Australia. Journal of Urban Health, 2004, 81, 448-452.	3.6	21
87	Development of a nurse-led primary healthcare service for injecting drug users in inner-city Sydney. Australian Journal of Primary Health, 2011, 17, 10.	0.9	21
88	Harnessing advances in computer simulation to inform policy and planning to reduce alcohol-related harms. International Journal of Public Health, 2018, 63, 537-546.	2.3	21
89	The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. Addiction, 2010, 105, 329-334.	3.3	20

Applications and Challenges for the Use of Phosphatidylethanol Testing in Liver Disease Patients (Mini) Tj ETQq0 0 0 rgBT /Overlock 10 7 2.49

#	Article	IF	CITATIONS
91	N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. Expert Opinion on Investigational Drugs, 2018, 27, 667-675.	4.1	20
92	A systematic review of evidence-based practice implementation in drug and alcohol settings: applying the consolidated framework for implementation research framework. Implementation Science, 2021, 16, 22.	6.9	20
93	Reluctance to Accept Alcohol Treatment by Alcoholic Liver Disease Transplant Patients: A Qualitative Study. Transplantation Direct, 2016, 2, e104.	1.6	19
94	Moderation of baclofen response by a GABA _B receptor polymorphism: results from the BacALD randomized controlled trial. Addiction, 2018, 113, 2205-2213.	3.3	19
95	Alcohol use disorder and the gut. Addiction, 2021, 116, 658-667.	3.3	19
96	Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology, 2021, 238, 1291-1302.	3.1	19
97	The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. International Journal of Drug Policy, 2015, 26, 1094-1102.	3.3	18
98	New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. Expert Opinion on Pharmacotherapy, 2021, 22, 1291-1303.	1.8	18
99	Transmission of hepatitis C virus by needle-stick injury in community settings. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1882-1885.	2.8	17
100	Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence. Journal of Substance Abuse Treatment, 2017, 74, 23-25.	2.8	17
101	Both ethanol and protein deficiency increase messenger RNA levels for pancreatic lithostathine. Life Sciences, 1996, 58, 485-492.	4.3	16
102	Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). BMJ Open, 2018, 8, e020745.	1.9	16
103	Relationship between hepatitis C virus subtypes and clinical features of liver disease seen in alcoholics. Journal of Hepatology, 1995, 22, 130-134.	3.7	15
104	Are primary health care centres that target injecting drug users attracting and serving the clients they are designed for? A case study from Sydney, Australia. International Journal of Drug Policy, 2013, 24, 326-332.	3.3	15
105	Harmonizing Post-Market Surveillance of Prescription Drug Misuse: A Systematic Review of Observational Studies Using Routinely Collected Data (2000–2013). Drug Safety, 2015, 38, 553-564.	3.2	15
106	Vitamin B $\langle sub \rangle 12 \langle sub \rangle$ supplementation futile for preventing demyelination in ongoing nitrous oxide misuse. Medical Journal of Australia, 2019, 211, 428.	1.7	15
107	Metabolism of Alcohol by the Human Stomach. Alcoholism: Clinical and Experimental Research, 2000, 24, 407-408.	2.4	14
108	Insomnia and excessive daytime sleepiness in women and men receiving methadone and buprenorphine maintenance treatment. Substance Use and Misuse, 2019, 54, 1589-1598.	1.4	14

#	Article	IF	Citations
109	Alcohol and the Pancreas. Alcoholism: Clinical and Experimental Research, 2001, 25, 244S-250S.	2.4	13
110	The medical complications of heroin use. Current Opinion in Psychiatry, 2005, 18, 257-263.	6.3	13
111	Correlates of Susceptibility to Hepatitis B among People Who Inject Drugs in Sydney, Australia. Journal of Urban Health, 2012, 89, 769-778.	3.6	13
112	Translating Evidence-Based Practice for Managing Comorbid Substance Use and Mental Illness Using a Multimodal Training Package. Journal of Dual Diagnosis, 2018, 14, 111-119.	1.2	13
113	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. Alcohol, 2018, 66, 1-7.	1.7	13
114	Implementation of evidence-based practice for alcohol and substance use disorders: protocol for systematic review. Systematic Reviews, 2020, 9, 25.	5.3	13
115	Supporting Aboriginal Community Controlled Health Services to deliver alcohol care: protocol for a cluster randomised controlled trial. BMJ Open, 2019, 9, e030909.	1.9	12
116	Designing, implementing and evaluating the overdose response with takeâ€home naloxone model of care: An evaluation of client outcomes and perspectives. Drug and Alcohol Review, 2020, 39, 55-65.	2.1	12
117	Reversal of central sleep apnoea with change from methadone to buprenorphine-naloxone: a case report. European Respiratory Journal, 2015, 46, 1202-1205.	6.7	11
118	Community attitudes towards harm reduction services and a newly established needle and syringe automatic dispensing machine in an inner-city area of Sydney, Australia. International Journal of Drug Policy, 2016, 27, 121-126.	3.3	11
119	Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial. Journal of Clinical Virology, 2016, 74, 66-72.	3.1	11
120	Executive Functioning Moderates Responses to Appetitive Cues: A Study in Severe Alcohol Use Disorder and Alcoholic Liver Disease. Alcohol and Alcoholism, 2019, 54, 38-46.	1.6	11
121	Spontaneously Occurring Antibodies to Parathyroid Hormone*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1744-1749.	3.6	10
122	Sexually transmitted infections, sexual risk behaviours and perceived barriers to safe sex among drug users. Australian and New Zealand Journal of Public Health, 2013, 37, 311-315.	1.8	10
123	A Review of Baclofen Overdoses in Australia: Calls to a Poisons Information Centre and a Case Series. Alcohol and Alcoholism, 2019, 54, 73-78.	1.6	10
124	High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: Preliminary findings from a pharmaco-fMRI study. European Neuropsychopharmacology, 2021, 46, 28-36.	0.7	10
125	Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial. Sports Medicine - Open, 2022, 8, 27.	3.1	10
126	CLINICAL UPDATE: Management of acute pancreatitis. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 189-197.	2.8	9

#	Article	IF	CITATIONS
127	Sample bias from different recruitment strategies in a randomised controlled trial for alcohol dependence. Drug and Alcohol Review, 2009, 28, 222-229.	2.1	9
128	Clinical Predictors of Outcome from an Australian Pharmacological Relapse Prevention Trial. Alcohol and Alcoholism, 2010, 45, 520-526.	1.6	9
129	Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. Journal of Addiction Medicine, 2017, 11, 10-18.	2.6	9
130	Neurometabolite Levels in Alcohol Use Disorder Patients During Baclofen Treatment and Prediction of Relapse to Heavy Drinking. Frontiers in Psychiatry, 2018, 9, 412.	2.6	9
131	Development of a joint mental-health and drug health assessment unit and short-stay unit. Australasian Psychiatry, 2019, 27, 374-377.	0.7	9
132	Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial. Alcohol and Alcoholism, 2019, 54, 272-278.	1.6	9
133	Evidence based models of care for the treatment of alcohol use disorder in primary health care settings: a systematic review. BMC Family Practice, 2020, 21, 260.	2.9	9
134	Intolerance of uncertainty and conditioned place preference in opioid addiction. PeerJ, 2018, 6, e4775.	2.0	9
135	Gastric metabolism of ethanol in Syrian golden hamster. Digestive Diseases and Sciences, 1995, 40, 2712-2716.	2.3	8
136	Overview of Substance Use and Treatment from Australia. Substance Abuse, 2014, 35, 304-308.	2.3	8
137	The impact of an automatic syringe dispensing machine in innerâ€city Sydney, Australia: No evidence of a â€~honeyâ€pot' effect. Drug and Alcohol Review, 2016, 35, 637-643.	2.1	8
138	Randomised controlled trial of integrated cognitive behavioural treatment and motivational enhancement for comorbid social anxiety and alcohol use disorders. Australian and New Zealand Journal of Psychiatry, 2021, 55, 207-220.	2.3	8
139	Support can increase use of the AUDIT in Australian Aboriginal Community Controlled Health Services: a cluster randomized trial. Addiction, 2021, 116, 2304-2315.	3.3	8
140	Training in Addiction Medicine in Australia. Substance Abuse, 2011, 32, 115-119.	2.3	7
141	Opportunistic and continuing health care for injecting drug users from a nurseâ€run needle syringe programâ€based primary healthâ€care clinic. Drug and Alcohol Review, 2012, 31, 114-115.	2.1	7
142	Individual versus teamâ€based caseâ€management for clients of opioid treatment services: An initial evaluation of what clients prefer. Drug and Alcohol Review, 2012, 31, 499-506.	2.1	7
143	Predictors of neonatal outcomes amongst a methadone- and/or heroin-dependent population referred to a multidisciplinary Perinatal and Family Drug Health Service. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2013, 53, n/a-n/a.	1.0	7
144	The Reluctance of Liver Transplant Participants with Alcoholic Liver Disease to Participate in Treatment for Their Alcohol Use Disorder: An Issue of Treatment Matching?. Alcoholism Treatment Quarterly, 2016, 34, 233-251.	0.8	7

#	Article	IF	CITATIONS
145	Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease. Current Addiction Reports, 2018, 5, 287-296.	3.4	7
146	Brain N-Acetyl Aspartate and associations with cognitive impairment in alcohol dependent patients. Journal of Clinical and Experimental Neuropsychology, 2020, 42, 111-117.	1.3	7
147	Baclofen modulates cardiovascular responses to appetitive cues in treatmentâ€seeking alcohol use disorder individuals. Human Psychopharmacology, 2020, 35, e2722.	1.5	7
148	Psychosocial Interventions for Reducing Suicidal Behaviour and Alcohol Consumption in Patients With Alcohol Problems: A Systematic Review of Randomized Controlled Trials. Alcohol and Alcoholism, 2021, 56, 17-27.	1.6	7
149	The role of clinical supervision in implementing evidence-based practice for managing comorbidity. Clinical Supervisor, The, 2021, 40, 158-177.	1.7	7
150	Forming a national multicentre collaboration to conduct clinical trials: Increasing highâ€quality research in the drug and alcohol field. Drug and Alcohol Review, 2010, 29, 469-474.	2.1	6
151	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. Antiviral Therapy, 2016, 21, 425-434.	1.0	6
152	Vertical transmission of hepatitis C: Testing and health are engagement. Journal of Paediatrics and Child Health, 2018, 54, 647-652.	0.8	6
153	Brain GABA levels are reduced in alcoholic liver disease: A proton magnetic resonance spectroscopy study. Addiction Biology, 2020, 25, e12702.	2.6	6
154	Implementation of a Multi-Modal Training Program for the Management of Comorbid Mental Disorders in Drug and Alcohol Settings: Pathways to Comorbidity Care (PCC). Journal of Dual Diagnosis, 2021, 17, 304-312.	1.2	6
155	Support for Aboriginal health services in reducing harms from alcohol: 2â€year service provision outcomes in a cluster randomized trial. Addiction, 2022, 117, 796-803.	3.3	6
156	GABAB Receptors and Alcohol Use Disorders: Clinical Studies. Current Topics in Behavioral Neurosciences, 2020, , 195-212.	1.7	6
157	"l'll never touch it again, doctor!―— harmful drinking after liver transplantation. Hepatology, 2007, 46, 1302-1304.	7.3	5
158	A primary healthcare clinic in a needle syringe program may contribute to HIV prevention by early detection of incident HIV in an injecting drug user. Australian and New Zealand Journal of Public Health, 2011, 35, 294-295.	1.8	5
159	Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol. Mental Health and Physical Activity, 2017, 13, 57-67.	1.8	5
160	Baclofen Response in Alcohol Dependent Patients Concurrently Receiving Antidepressants: Secondary Analysis From the BacALD Study. Frontiers in Psychiatry, 2018, 9, 576.	2.6	5
161	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. Drug and Alcohol Review, 2018, 37, 887-896.	2.1	5
162	Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). Trials, 2018, 19, 443.	1.6	5

#	Article	IF	CITATIONS
163	Australian treatment outcome study: protocol for the $18\hat{a}\in$ 20-year follow-up of a prospective longitudinal cohort examining the natural history of heroin dependence and associated mortality, psychiatric and physical health, and health service use. BMJ Open, 2020, 10, e039226.	1.9	5
164	The impact of alcohol pharmacotherapies on public health in Australia is limited by low prescribing rates. Public Health Research and Practice, 2016 , 26 , .	1.5	5
165	â€~Nurse specialling': Direct nursing observation in the emergency department compared to other wards of an urban teaching hospital in Sydney. Australasian Psychiatry, 2018, 26, 276-280.	0.7	4
166	Genetic Polymorphisms on OPRM1, DRD2, DRD4, and COMT in Young Adults: Lack of Association With Alcohol Consumption. Frontiers in Psychiatry, 2020, 11, 549429.	2.6	4
167	How intoxicated are you? Investigating self and observer intoxication ratings in relation to blood alcohol concentration. Drug and Alcohol Review, 2021, 40, 1173-1177.	2.1	4
168	Alcohol and the Pancreas. Alcoholism: Clinical and Experimental Research, 2001, 25, 244S-250S.	2.4	4
169	Sex as a Potential Moderator for Baclofen Response in the Treatment of Alcohol Dependence. Frontiers in Global Women S Health, 2022, 3, 807269.	2.3	4
170	Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial. Substance Abuse and Rehabilitation, 2012, 3, 43.	4.8	3
171	Reward and punishment-based compound cue learning and generalization in opiate dependency. Experimental Brain Research, 2017, 235, 3153-3162.	1.5	3
172	A pilot study of escape, avoidance, and approach behaviors in treated alcohol-dependent males. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 601-614.	1.3	3
173	Evidence-based models of care for the treatment of alcohol use disorder in primary health care settings: protocol for systematic review. Systematic Reviews, 2019, 8, 275.	5.3	3
174	Treatment of alcohol problems: current status and future directions. Medical Journal of Australia, 2021, 215, 315-316.	1.7	3
175	More than three times as many Indigenous Australian clients at risk from drinking could be supported if clinicians used AUDIT-C instead of unstructured assessments. Addiction Science & Elinical Practice, 2022, 17, 23.	2.6	3
176	The evaluation of the role of technology in the pathways to comorbidity care implementation project to improve management of comorbid substance use and mental disorders. Journal of Multimorbidity and Comorbidity, 2022, 12, 263355652210969.	2,2	3
177	Quality of life of women living with hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 1329-1331.	2.8	2
178	Hepatitis B vaccination for people who inject drugs. Lancet, The, 2015, 385, 115.	13.7	2
179	Characteristics of Suicide Attempters and Ideators in a Clinical Sample of Substance Users. Substance Use and Misuse, 2018, 53, 1811-1818.	1.4	2
180	What are people saying on social networking sites about the Australian alcohol consumption guidelines?. Medical Journal of Australia, 2021, 214, 105.	1.7	2

#	Article	IF	Citations
181	Should we be using eâ€vouchers to compensate research participants? Acceptability among opioid agonist treatment clients. Drug and Alcohol Review, 2021, 40, 1356-1357.	2.1	2
182	Variability in insulin pharmacokinetics following high-dose insulin therapy. Clinical Toxicology, 2022, 60, 389-391.	1.9	2
183	Developing a model of care for substance use in pregnancy and parenting services, Sydney, Australia: Service provider perspectives. Journal of Substance Abuse Treatment, 2021, 131, 108420.	2.8	2
184	Comment on pill testing review. Internal Medicine Journal, 2020, 50, 1596-1597.	0.8	2
185	Gastrointestinal Disorders Related to Alcohol and Other Drug Use. , 2021, , 1077-1097.		2
186	Problem drinking - detection and assessment in general practice. Australian Family Physician, 2011, 40, 570-4.	0.5	2
187	A pilot study of a text message and online brief contact intervention following self-harm or a suicide attempt: A mixed methods evaluation. General Hospital Psychiatry, 2022, 76, 1-2.	2.4	2
188	Charles S. Lieber, 1931-2009. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 941-942.	2.8	1
189	Daily experiences of hangover severity and food consumption in young adults. British Journal of Health Psychology, 2022, 27, 468-483.	3.5	1
190	Psychostimulant-related health service demand in an inner-city hospital, 2012–2015. Public Health Research and Practice, 2018, 28, .	1.5	1
191	Antioxidants status and physical fitness in seniors aerobically trained and supplemented with a multivitamin drink. Forum of Nutrition, 2003, 56, 261-2.	3.7	1
192	Alcohol Related Harm: Knowledge Assessment of Medical and Nursing Staff in a General Hospital. , 2018, 55, 32-36.		1
193	Management of alcohol and other drug issues in Special Health Accommodation during the <scp>COVID</scp> â€19 Delta variant outbreak in Sydney, 2021. Drug and Alcohol Review, 0, , .	2.1	1
194	NSW Alcohol Summit: getting a better grip on our favourite drug. Medical Journal of Australia, 2003, 179, 521-522.	1.7	0
195	Genetic disorders in pancreatitis. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 939-939.	2.8	0
196	The Treatment of Drinking Problems: a Guide for the Helping Professions. Addiction, 2004, 99, 135-135.	3.3	0
197	Challenge for doctors and policy makers. BMJ: British Medical Journal, 2006, 332, 277.2-278.	2.3	0
198	A novel mechanism of ovel mechanism of alcohol-induced hepatic stellate cell activation via secreted phosphoprotein 1 pathway. Journal of Clinical and Experimental Hepatology, 2013, 3, S22.	0.9	0

#	Article	IF	CITATIONS
199	Secreted phosphoprotein 1 in chronic liver injury. Journal of Clinical and Experimental Hepatology, 2013, 3, S51-S52.	0.9	0
200	Identification of smoking status in the Census is needed, but what about the healthcare system?. Australian and New Zealand Journal of Public Health, 2019, 43, 96.	1.8	0
201	118â€Case series: subacute combined degeneration of the spinal cord in vitamin B12-replete recreational nitrous oxide abusers. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A38.2-A39.	1.9	0
202	Are bottle shops using Twitter to increase advertising or encourage drinking during COVIDâ€19?. Australian and New Zealand Journal of Public Health, 2021, 45, 391-393.	1.8	0
203	Criminal Justice And Addiction Treatment: Best Practices in Addiction Treatment In the Criminal Justice System. Canadian Journal of Addiction, 2009, 1, 18.	0.4	0
204	Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV) Journal of Clinical Oncology, 2018, 36, TPS10128-TPS10128.	1.6	0
205	Results of crossover phase II component of randomized placebo-controlled trial evaluating oral THC/cannabis extract for refractory chemotherapy-induced nausea and vomiting (CINV) Journal of Clinical Oncology, 2020, 38, 12008-12008.	1.6	0
206	Problem drinking-management in general practice. Australian Family Physician, 2011, 40, 576-82.	0.5	0
207	Preliminary results of a controlled educational intervention on alcohol related harm among medical students with a 12-month follow-up., 2018, 55, 37-39.		0
208	Effects of service-wide support on regularity of alcohol screening of clients in Australian Aboriginal and Torres Strait Islander Community Controlled Health Services: a cluster randomised trial. Addiction Science & Dirical Practice, 2022, 17, 13.	2.6	0